- Home
- HIVE vs XNCR Comparison
HIVE vs XNCR Comparison
Compare HIVE & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- XNCR
- Stock Information
- Founded
- HIVE 1987
- XNCR 1997
- Country
- HIVE United States
- XNCR United States
- Employees
- HIVE N/A
- XNCR N/A
- Industry
- HIVE
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- HIVE
- XNCR Health Care
- Exchange
- HIVE Nasdaq
- XNCR Nasdaq
- Market Cap
- HIVE 459.0M
- XNCR 547.8M
- IPO Year
- HIVE N/A
- XNCR 2013
- Fundamental
- Price
- HIVE $2.52
- XNCR $8.41
- Analyst Decision
- HIVE Strong Buy
- XNCR Buy
- Analyst Count
- HIVE 6
- XNCR 9
- Target Price
- HIVE $6.83
- XNCR $25.00
- AVG Volume (30 Days)
- HIVE 17.4M
- XNCR 718.6K
- Earning Date
- HIVE 08-14-2025
- XNCR 08-06-2025
- Dividend Yield
- HIVE N/A
- XNCR N/A
- EPS Growth
- HIVE 42.43
- XNCR N/A
- EPS
- HIVE 0.34
- XNCR N/A
- Revenue
- HIVE $128,649,000.00
- XNCR $146,929,000.00
- Revenue This Year
- HIVE $164.89
- XNCR N/A
- Revenue Next Year
- HIVE $60.62
- XNCR $28.84
- P/E Ratio
- HIVE $7.33
- XNCR N/A
- Revenue Growth
- HIVE 4.47
- XNCR N/A
- 52 Week Low
- HIVE $1.26
- XNCR $6.92
- 52 Week High
- HIVE $5.54
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- HIVE 67.34
- XNCR 55.89
- Support Level
- HIVE $2.23
- XNCR $7.13
- Resistance Level
- HIVE $2.46
- XNCR $7.99
- Average True Range (ATR)
- HIVE 0.12
- XNCR 0.53
- MACD
- HIVE 0.03
- XNCR 0.06
- Stochastic Oscillator
- HIVE 98.15
- XNCR 94.90
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.